KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cost of Revenue: 2018-2024

Historic Cost of Revenue for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Dec 2024 value amounting to $306.5 million.

  • Alnylam Pharmaceuticals' Cost of Revenue rose 140.58% to $197.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $512.1 million, marking a year-over-year increase of 85.65%. This contributed to the annual value of $306.5 million for FY2024, which is 14.28% up from last year.
  • As of FY2024, Alnylam Pharmaceuticals' Cost of Revenue stood at $306.5 million, which was up 14.28% from $268.2 million recorded in FY2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' Cost of Revenue peaked at $306.5 million during FY2024, and registered a low of $74.2 million during FY2020.
  • Its 3-year average for Cost of Revenue is $238.3 million, with a median of $268.2 million in 2023.
  • Data for Alnylam Pharmaceuticals' Cost of Revenue shows a peak YoY spiked of 196.01% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Cost of Revenue stood at $74.2 million in 2020, then skyrocketed by 55.02% to $115.0 million in 2021, then grew by 21.89% to $140.2 million in 2022, then surged by 91.35% to $268.2 million in 2023, then increased by 14.28% to $306.5 million in 2024.